Drug Therapy for Rheumatoid Arthritis in Adults
Summary of Results: Comparative Benefits of Biologic DMARDs Used in Combination
Two randomized controlled trials examined the benefits of combining two biologic DMARDs when compared with biologic DMARD monotherapy. The patient populations were those patients with longstanding active rheumatoid arthritis, rather than those with early disease. No statistically significant differences were noted in disease activity, function, or quality-of-life indices.
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic DMARD | disease activity | symptom response | quality of life
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.